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Abstract
A novel dendritic-like cell subset termed L-DC was recently identified in murine spleen based on marker expression of a homogeneous cell pop-
ulation derived from long-term culture of neonatal spleen. The function of L-DC is distinct from other splenic dendritic and myeloid cell subsets
because of their high endocytic capacity and their ability to cross-present antigen to CD8+ T cells. This paper shows the subset to be unique to
spleen and blood, with a similar, but possibly functionally distinct subset also present in bone marrow. The prevalence of the subset is low;
~6% of all dendritic and myeloid cells in the spleen and ~5% in blood. However, they are a distinct cell type on the basis of marker expression,
and endocytic and T-cell stimulatory capacity. Attempts to identify an enriched population of these cells in mutant mouse strains with reported
increases in myelopoiesis showed either a lack of L-DC or an altered phenotype reflective of the phenotype of the mouse strain.
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Introduction
The importance of dendritic cells (DC) in the immune system as the
mediators between innate and adaptive immunity has only recently
become apparent. As a result, this field of study is relatively new and
DC are emerging to be a complex cell type with extensive variability in
phenotype and function. Murine DC can largely be divided into three
types: migratory DC, conventional (c)DC and plasmacytoid (p)DC.
Migratory DC, such as Langerhans cells, develop in the periphery and
migrate to lymph nodes following encounter with antigen to activate T
cells [1, 2]. Conventional DC are blood-derived, reside in the spleen,
and can be further divided into subsets based on marker expression.
Functional definition of the cDC subsets, namely CD8a+ cDC
(CD11c+CD11bMHC-II+) and CD8a cDC (CD11c+CD11b+MHC-II+),
has proven difficult. CD8a+ cDC are generally thought to be cross-
presenting cells inducing a CD8+ T-cell response [3] with an ability to
induce Th1 CD4+ T cells through production of the Th1-inducing cyto-
kine interleukin (IL)-12, and can also produce the type I interferons
IFN-a and IFN-b [4–6]. CD8a cDC are classified as Th2-inducing
cells [4, 5]; however, they have also been reported to produce IL-12
as well as IFN-c [6, 7], and have cross-presenting capacity in some
model infections [8]. Plasmacytoid DC are an IFN-a-producing subset
involved in virus clearance at the level of the innate immune response,
later maturing to become DC capable of inducing adaptive immune
responses [9].
This laboratory has identified a dendritic-like subset that devel-
ops as a homogeneous population of cells in vitro following culture
of whole spleen from neonatal mice [10]. These long-term cultures
maintain production of cells over a period of years, through devel-
opment of large mature cells along with progenitors and precur-
sors, which are maintained in the cultures. Long-term culture DC
(L-DC) have a characteristic phenotype as CD11cloCD11bhiC-
D8aMHC-II cells, which are very large in terms of forward scat-
ter (FSC) when examined using flow cytometry [10]. On the basis
of the distinct marker expression and size of L-DC, we recently
reported an in vivo equivalent dendritic-like cell with high endocytic
and cross-presenting capacity in vitro [11]. The L-DC marker
expression relative to other DC subsets as reported in Tan et al.
[11] is summarized in Table 1. Here, we characterize L-DC in terms
of prevalence in relation to other known DC subsets in spleen and
other tissues. Given their high CD11b expression, L-DC are thought
to be of myeloid origin. To determine the effect of mutations
affecting myelopoiesis on the relative prevalence of cDC, pDC and
L-DC, we investigate their tissue distribution and lineage relation-
ships and examine the prevalence of these cells in normal mouse
lymphoid tissues and in two mutant strains of mice where myelo-
poiesis has been affected.
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Materials and methods
Animals
Specific pathogen-free female C57BL/6J (CD45.2+), C57BL/6J.SJL
(CD45.1+) and CBA/H mice were obtained from the John Curtin School
of Medical Research [JCSMR: Australian National University (ANU),
Canberra] and used at 6 weeks or 8 days of age. Organs from sanroque
mice [12] were donated by Dr. Carola Vinuesa (JCSMR). Rag KO
(Rag/) mice were obtained from the Australian Phenomics Facility
(APF: ANU). Ovalbumin-specific MHC-I- and MHC-II-restricted TCR-
transgenic (tg) mice [OT-I (anti-Kb) and OT-II (anti-IAb), respectively]
were obtained from the APF. Mice were housed and handled according
to protocols approved by the Animal Experimentation Ethics Committee
at the ANU and killed by cervical dislocation.
Tissue culture
DMEM was supplemented with 10% foetal calf serum (JRH Biosciences,
Lenexa, KS, USA), 10 mM Hepes (JRH Biosciences), 2 mM L-glutamine
(JRH Biosciences), 100 U/ml penicillin (JCSMR), 100 lg/ml streptomy-
cin (JCSMR) and 5 9 105M 2-mercaptoethanol (BDH Ltd., Poole, Uni-
ted Kingdom). This is referred to as supplemented DMEM (sDMEM).
Cells were maintained in 5% CO2 in air and 97% humidity at 37°C. For
estimation of cell number and viability, cells were stained with trypan
blue (0.4%/saline; Gibco BRL, Grand Island, NY, USA).
Preparation of lymphoid cells ex vivo
For preparation of single cell suspensions, bone marrow (BM) was iso-
lated from the femur of a C57BL/6J mouse. Marrow was flushed from
the bone cavity by injection of DMEM by using a syringe equipped with
a 26-G needle. Cells were dissociated by pipetting and resuspended in
sDMEM. After sedimentation, red blood cells (RBC) were removed by
lysis in RBC lysis buffer (140 mM NH4Cl, 17 mM Tris base in deionised
water). Cells were then washed twice in sDMEM and counted. For prep-
aration of thymocytes and cells from the mesenteric lymph node
(MLN), tissues were dissociated by pressing through a fine mesh sieve.
For isolation of splenocytes, dissected spleen was pressed through a
fine mesh sieve. Cells were resuspended in sDMEM, RBC lysed and
cells washed as described for BM. Cells were counted after the final
wash.
For T- and B-cell depletion, splenocytes were incubated with
0.25 lg/ml biotinylated anti-CD19 antibody (eBiosciences, San Diego,
CA, USA)/108 cells (B cells), and 0.2 lg/ml biotinylated anti-Thy1.2 anti-
body (eBiosciences)/108 cells (T cells) in 1 ml/108 cells for 10 min. on
ice in labelling buffer (0.5%/2 mM EDTA/PBS). Cells were washed twice
with labelling buffer and anti-biotin microbeads (Miltenyi Biotec, Auburn,
CA, USA) were added at 13 ll beads/108 cells in 1 ml/108 cells and
incubated for 25 min. on ice. Cells were washed once in labelling buffer
and resuspended in 500 ll of the same buffer. The LS depletion column
(Miltenyi Biotec) was prepared by placing it in a magnet (SuperMacs;
Miltenyi Biotec) and washing once with 3 ml labelling buffer. The cell
suspension was then run through the column and collected in a new
tube, followed by three washes with 3 ml labelling buffer. Cells were
pelleted and resuspended in sDMEM for counting and antibody staining.
Antibody staining of cells and analysis and
sorting by using flow cytometry
Fluorochrome-conjugated antibodies were used for cell surface staining
to identify subsets of interest. They were purchased as affinity-purified
preparations from either eBiosciences, BD Pharmingen (San Jose, CA,
USA) or Molecular Probes (Eugene, OR, USA), conjugated with either
fluorochromes or biotin. Anti-CD16/32 (clone: 93), anti-CD11c-allophyc-
ocyanin (APC) (clone: N418), anti-CD11b-phycoerythrin (PE)-Cy7 (clone:
M1/70), anti-CD19-biotin (clone: eBiolD3), anti-Thy1.2-biotin (clone: 30-
H12), anti-CD45RA-biotin (clone: RA3-6B2) and anti-CD45RA-PE (B220,
clone: RA3-6B2) were obtained from eBiosciences. Anti-CD8a-PE
(clone: 53-6.7), anti-IAb-fluoresceinisothiocyanate (FITC) (clone: AF6-
120.1) and anti-IAb-biotin (clone: 25-9-17) were obtained from BD
Pharmingen. Streptavidin-APC-AlexaFluor-750 was obtained from Molec-
ular Probes. All antibodies were titrated prior to use to determine the
concentration giving minimum saturation binding.
For staining, ~5 9 105 cells were sedimented into the wells of a flexi-
ble 96-well polystyrene microtitre plate (Corning, Tewksbury, MA, USA).
Cells were resuspended in anti-CD16/32 (FcBlock) prior to staining in a
primary antibody cocktail. Where necessary, secondary reagents were
added before resuspension in DMEM/1%FCS/0.1%NaN3 before transfer
to cluster tubes (Corning) for analysis by using a flow cytometer (Becton
Dickinson LSRII, San Jose, CA, USA). Prior to analysis, propidium iodide
(PI: 100 lg/ml) was added for dead cell discrimination. Background bind-
ing was determined by using isotype control antibodies corresponding to
each fluorescence-conjugated antibody used, and gates were set by using
this information as well as internal positive and negative cell subsets to
identify specific staining. Analysis was performed using BD FACSDiva
software (Becton Dickson) and Flow Jo software (Tristar, Phoenix, AZ,
USA). For fluorescence-activated cell sorting, cells were processed as
above before being sorted at the sorting facility at the JCSMR.
Endocytic capacity of cells
The in vivo endocytic capacity of isolated DC subsets was tested by
using FITC-conjugated ovalbumin (OVA). OVA-FITC (10 mg/ml) was
injected i.v. into mice in 300 ll HBSS. Mice were left for 24 hrs before
sacrifice and spleen removal. Spleens were dissociated and stained with
antibodies.
Table 1 Marker expression on L-DC compared with in vivo splenic
DC subsets
L-DC CD8a+ cDC CD8a cDC pDC Monocytes
CD11c Lo Hi Hi Lo 
CD11b Hi  Lo  +
CD8a  +  + 
MHC-II  + + Lo 
MHC-I + + + + /Lo
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CFSE labelling
Cells were labelled with CFSE for analysis of reduction in label as a mea-
sure of cell division. Cells were washed and then resuspended in DMEM
(100 ll/107 cells). One ll CFSE, final concentration 10 lg/ml, was added
and vortexed immediately. Cells were incubated for 5 min. at room tem-
perature with agitation before adding 1 ml sDMEM and washing twice.
OT-I and OT-II T-cell stimulation assays
Antigen-specific T-cell stimulation capacity of DC was assessed by using
CD8+ T cells obtained from OT-I mice and CD4+ T cells obtained from OT-
II mice. These mice express TCR transgenes specific for OVA presented
on either MHC-I (OT-I) or MHC-II (OT-II). Hen egg lysozyme (HEL; Sigma-
Aldrich, St. Louis, MO, USA) was used as a negative control antigen.
Dendritic cells were pulsed in vivo with either 0.5 mg HEL or 0.5 mg
OVA administered through i.v. injection. After 24 hrs, spleen was col-
lected and the DC subsets stained and sorted as described above. CD4+
and CD8+ T cells were isolated from LN of OT-II and OT-I TCR-tg mice by
magnetic depletion as described above. Sorted cells were incubated with
CFSE-labelled T cells (1 9 105 for OT-I, and 1 9 104 for OT-II) in 96-well
plates at the following ratios, and collected at 4 days for analysis as for
the MLR. DC: T cells for OT-I: 1:10 and 1:100, and for OT-II: 1:1 and 1:5.
Results
Identification of cells with
CD11cloCD11bhiCD8aMHC-II phenotype in
murine spleen, BM and blood
As described previously by Tan et al. in 2011 [11], the in vivo
counterpart to L-DC represent a distinct subset of CD11cloCD11bhi
CD8aMHC-II cells in spleen compared with cDC, pDC and mono-
cytes, and are distinguishable by the selected markers as well as by
their characteristically large size. Each of the splenic DC subsets is
identified here by using the same gating strategy (Fig. 1). This gating
protocol was applied to BM (Fig. 2A), MLN (Fig. 2B) and blood
(Fig. 2C) to identify any similar cells. L-DC-like cells, as well as mono-
cytes and p-preDC, were identified in BM and blood but not in MLN.
L-DC represent a small but significant
subpopulation in relation to other DC subsets
Prevalence of L-DC in each organ relative to cDC, pDC and monocytes
was analysed by identification of each subset and calculation of its
percentage in relation to total leucocyte number in BM or spleen,
accounting for per cent depletion of T and B cells in the case of spleen
(data not shown): (% cells amongst T-/B-depleted organ)/100 9 (%
T/B depletion).
Prevalence of each subset amongst total dendritic (CD11c+) and
myeloid (CD11b+) cells was also calculated: (% subset of total
organ)/(% dendritic & myeloid cells in organ) 9 100.
Means  SD were calculated for all animals tested (n = 7 for
spleen, n = 6 for BM and MLN, and n = 2 for blood) and data are
shown in Table 2. L-DC represent the smallest subset of DC in spleen,
comprising just 0.07  0.02% of all spleen leucocytes (data not
shown) and 5.86  0.30% of all CD11c+ and/or CD11b+ dendritic/
myeloid cells (Table 2). The most abundant subsets in spleen were
CD8a cDC and monocytes, representing equal proportions of the
dendritic/myeloid fraction of spleen: 30.20  13.05% for CD8a cDC
and 31.00  13.08% for monocytes. It is not clear whether this vari-
ation reflects natural variation between animals or experimental error
related to preparation and staining. CD8a+ cDC and p-preDC reflected
similar proportions (~17%) of all dendritic/myeloid cells.
In BM, cells resembling L-DC represent the smallest subset
amongst identified dendritic/myeloid cells with an average representa-
tion of 7  1.5%. Plasmacytoid-preDC represent a very variable pop-
ulation, making up 12.67  5% of dendritic/myeloid cells. Again, this
could reflect variation between animals or between experiments.
Monocytes were by far the largest subset in BM, representing
80.17  5% of all dendritic/myeloid cells. No L-DC were detected in
MLN. The DC subsets detected in blood were L-DC (5  2%),
p-preDC (12  1%) and monocytes (82  1%) in a composition
similar to that observed in BM.
L-DC have a highly endocytic phenotype
It has already been established that, compared to cDC and mono-
cytes, L-DC are highly endocytic when pulsed with antigen in vitro,
and are capable of activating CD8+ T cells in a mixed lymphocyte
reaction [11]. To further investigate their functional capacity in terms
of their ability to take up antigen in vivo, mice received 3 mg FITC-
conjugated OVA i.v. Mice were killed 24 hrs later and spleens stained
for DC subsets to determine OVA-FITC uptake. Figure 3A shows high-
est level of uptake by monocytes and L-DC (~90% of cells). Uptake
by cDC was comparatively low (9% and 30% for CD8a+ cDC and
CD8a cDC, respectively).
In an attempt to distinguish L-DC from monocytes based on func-
tion, DC subsets were sorted from animals that had been pulsed with
OVA antigen in vivo as described above. The sorted cells were then
incubated with CFSE-stained CD4+ or CD8+ T cells from mice express-
ing OVA-specific TCR (OT-II or OT-I mice), respectively. APCs and T
cells were co-cultured with or without 3 lg lipopolysaccharide (LPS)
for 4 days before analysis of cell proliferation by flow cytometry. The
T-cell proliferative response was therefore related to in vivo uptake
capacity for antigen by each subset.
As shown in Figure 3B, the strongest effect on CD8+ OT-I T-cell
proliferation was induced by L-DC, but only after culture in the pres-
ence of LPS. This suggests that L-DC are very capable activators of
OT-I T cells, and are both accessible to blood-borne antigen and capa-
ble of high uptake compared with other subsets. In particular, whilst
monocytes and L-DC have very similar marker expression (Table 1),
monocytes had no capacity to stimulate either CD4+ or CD8+ T cells.
None of the isolated subsets showed particularly high capacity to
activate OT-II CD4+ T cells. T-cell proliferation was weak, but OVA-
specific. A response was seen for freshly isolated CD11c+ splenic DC
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and for L-DC, although the latter response was not improved by addi-
tion of LPS (Fig. 3C).
Prevalence of L-DC in sanroque animals
To investigate possible sources of a higher yield of L-DC, we investi-
gated their prevalence in mutant mouse strains. As L-DC are thought
to derive from the myeloid lineage, two available mutant mouse
strains with a known increase in myelopoiesis were investigated: san-
roque [12] and Rag/. Both strains are on the same C57BL/6J
genetic background as the wild-type (+/+) mice analysed above so
that any perturbation in L-DC number in mutant strain would there-
fore be due entirely to the mutation.
Sanroque mice were developed by Prof. Chris Goodnow and Dr.
Carola Vinuesa (JCSMR: ANU), and lack the ubiquitin ligase Roquin
[12]. Mice homozygous for the mutation are labelled san/san. These
mice have severe autoimmune disease, and all develop systemic
lupus erythematosus. Mice are in a perpetual state of inflammation
because of autoimmunity [13] and appear to have a higher prevalence
of myeloid cells [12]. Consequently, it was thought that the sanroque
mouse model may show an enriched population of L-DC, with or
without other myeloid lineage cells.
The presence of L-DC in mutants was checked by staining for DC
markers as for +/+ mice. Flow cytometry gates from the +/+ control
were overlaid on to those for mutant mice. Circular gates, shown in
Figure 4, were then used to denote populations present in mutant,
but not +/+ animals. Spleen (A), BM (B), and mesenteric (data not
shown) and cervical LN (CLN) (C) were prepared for analysis. Cervical
lymph nodes were taken from these animals because of their obvious
enlargement.
Figure 4 shows how the general profile of DC subsets in
spleen, BM and CLN of san/san mice differs from that of +/+
mice. The CD11bhiMHC-II population gated from the +/+
Fig. 1 Identification of DC subsets in the spleen. The prevalence of L-DC in relation to other DC subsets was examined by antibody staining of dis-
sociated leucocytes isolated from red blood cell-lysed spleen, BM, LN and thymus. Apart from CD11b and CD11c expression, DC subsets can be
further delineated according to CD8a and MHC-II expression. Cells were stained with fluorochrome-labelled antibodies specific for CD11c, CD11b,
CD8a and MHC-II. Dead cells were first gated out as PI+, followed by analysis of the expression of CD11c versus CD8a, and then CD11b versus
MHC-II. DC subsets were categorized after delineation of CD11clo and CD11chi subsets. Cross-hairs were set to exclude background staining on the
basis of isotype control antibodies. Side scatter (SSC) versus forward scatter (FSC) plots provide an extra parameter for identification of cells based
on granularity and size, respectively.
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CD11cloCD8a cell subset has been classified as L-DC, and this
population shows characteristic high FSC (data not shown). How-
ever, it appears that any L-DC have gained MHC-II expression in
san/san mice, a phenotype that is possible because of the constit-
utive inflammatory state of san/san animals. Several other cell
populations in san/san spleen also appear to have altered pheno-
types, such as monocytes, which have gained MHC-II expression.
Furthermore, pDC derived from the CD11cloCD8a gate have
gained MHC-II, and perhaps low CD11b expression, which could
represent activated pDC.
Fig. 2 Identification of DC subsets in BM, blood and MLN. The prevalence of L-DC in relation to other DC subsets in BM (A), MLN (B) and blood
(C) was examined as described in Figure 1.
1612 ª 2013 The Authors.
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L-DC are not present in BM of san/san mice in any significant
number, such that their existence is debatable. As observed in
+/+ mice, there is no detectable population of pDC; however, san/
san animals appear to have a significant population of p-preDC
(Fig. 4B). There is also increased representation of a
CD11cCD11bloCD8aMHC-II subset (Fig. 4B) that may repre-
sent an expanded population of myeloid precursors. In san/san
BM, monocytes dominate in cell number, representing roughly
double the percentage present in +/+ animals (Fig. 4B and
Table 2). This reflects the previously observed increase in cells of
the myeloid lineage in san/san mice [12].
Dendritic cells subsets in MLN (data not shown) and CLN
(Fig. 4C) of san/san mice differ noticeably from those in +/+ mice. A
population of CD11cloCD11bhiCD8aMHC-IIlo cells is present, which
reflect activated myeloid DC in phenotype, and possibly activated L-
DC, although their size on FSC is not as large as L-DC detected in +/+
spleen and BM, and cells also express MHC-II.
Table 2 contains a summary of the percentage distribution of
each identifiable dendritic and myeloid cell subset amongst total
spleen, BM and CLN dendritic/myeloid cells. These data are based on
mean  SD (n = 2). In the spleen, percentages of all DC subsets are
reduced by about half in san/san mice compared with +/+ animals,
with the exception of CD8a+ cDC, whose percentages remain similar,
although not statistically significant (P ≤ 0.05). The drop in mono-
cytes observed in the spleen could reflect inflammation-induced
migration to blood, where levels of myeloid-derived cells are unchar-
acteristically high.
L-DC are absent in Rag/ mice
Rag/ mice lack the gene encoding recombinases essential for rear-
rangement of TCR and immunoglobulin genes in T and B cells. In the
absence of T- and B-cell development, these mice have increased my-
elopoiesis. Monocytes, cDC and pDC are all much harder to identify
as clear subsets in spleen of Rag/ compared with +/+ animals. The
majority of cells are smaller in size and reflect myeloid or DC precur-
sors. No population of L-DC was detectable in the spleen (Fig. 5A).
Major populations of CD11cloCD11blo and CD11cCD11blo cells
reflect small undifferentiated cells. This expanded population is con-
sistent with less mature myeloid cell development because of the
absence of T cell-derived colony-stimulating factors and cytokines. L-
DC are detectable in Rag/ BM in numbers less than in +/+ (Fig. 5B
and Table 2). Monocyte and p-preDC populations are also detected.
As with the spleen, there is an increased number of CD11c cells,
reflecting undifferentiated cells. The layout of cell populations in BM
from Rag/ mice was very similar to that in +/+ mice, suggesting no
significant effect of the mutation on BM cell populations apart from
the reduced number of L-DC (Fig. 5B). This contrasts with spleen DC
subset development, which must be dependent on T/B-derived hae-
matopoietic factors. The populations present in Rag/ MLN appear
to be similar to those present in +/+ mice, except that the cDC popu-
lations have higher levels of CD11b expression (Fig. 5C). Relative per-
centages of each subset are summarized in Table 2. This shows that
Rag/ spleen contains only cDC and pDC, and no L-DC or mono-T
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cytes, with the per cent of CD8a and CD8a+ cDC dramatically
reduced, as are L-DC percentages in BM.
Discussion
This paper aims to further characterize L-DC on the basis of presence
in lymphoid organs other than the spleen and the relative size of the
cell population. In keeping with these aims, populations of cells
matching L-DC marker expression were clearly present as distinct
populations in spleen, blood and also BM, representing ~6, ~5 and
~7% of all DC and monocytes in the spleen, blood and BM, respec-
tively. Study of the steady-state function of L-DC is necessary to fur-
ther characterize this unique subset. Moreover, the relationship
between the populations identified in spleen and BM needs to be
established. Based on evidence from long-term cultures, L-DC are
spleen-derived cells, so it is important to establish the origin of the
population identified in BM in terms of the site of development and
the source of the precursor. Previous work in the laboratory has
shown that in vitro culture of BM cells, probably containing HSC, over
permissive spleen-derived stroma gives rise to L-DC [14], reflecting
the hypothesis that L-DC derive from HSC and are directed towards
L-DC by the spleen stroma [15]. It remains to be seen if BM contains
a similar L-DC-directing supportive cell line. Preliminary functional
studies performed on both spleen- and BM-derived L-DC show that
BM L-DC may have less capacity to activate T cells compared with
spleen-derived L-DC.
In this paper, we investigated the presence of L-DC in lymphoid
organs. It is also possible that these cells are present in tissue sites,
such as the gut or the skin. Given the lack of L-DC in mesenteric
lymph nodes, however, which drain the gut, it is unlikely that this sub-
set is present at this site. Furthermore, previous studies have shown
that L-DC lack langerin expression and are therefore not likely to be
skin-related. The fact that L-DC are suggested to develop in the
spleen from HSC in a specialized niche [15] suggests that the cells
have a specialised role within this organ. Study of L-DC prevalence in
other organs, however, is a possible direction of future investigations.
It is clear that L-DC represent a cell population distinct from cDC
and pDC due particularly to their characteristically low CD11c and
high CD11b expression. High levels of CD11b on the cell surface sug-
gest that the cells are of myeloid origin. Their presence in the spleen
could indicate a role in screening blood for either pathogen-related
Fig. 3 Endocytic and stimulatory capacity of splenic DC subsets. (A) The endocytic capacity of splenic DC subsets was tested through i.v. delivery
of FITC-conjugated OVA 24 hrs before the animals were killed. Spleens were then collected and stained for DC markers as described previously.
Percentages of cells taking up were OVA determined, with gating based on animals not receiving FITC-OVA. (B and C) The ability of splenic DC sub-
sets to take up antigen and present to T cells was investigated by i.v. administration of OVA or hen egg lysozyme (HEL; negative control) as in (A)
prior to isolation of DC subsets by fluorescence-activated cell sorting. CD4+ or CD8a+ T cells were isolated from OT-II or OT-I mice, respectively,
through magnetic bead depletion and labelled with CFSE. Antigen-presenting cells were then co-cultured with T cells for 4 days in the presence or
absence of LPS. (B) Expansion of CD4+ T cells, and (C) expansion of CD8a+ T cells. Freshly isolated and in vitro-stimulated CD11c+ DCs (f-DC) were
used as a positive control for the assay.
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Fig. 4 Distribution of dendritic/myeloid
subsets in sanroque mice. Spleen, BM and
LN cells from two 6-month-old female
sanroque (san/san; C57BL/6J) mice were
prepared and stained with antibody as
described previously in the legend to Fig-
ure 1. Representative analysis of one
mouse is shown. Cross-hairs delineated
background binding because of isotype
control antibodies and identifiable subsets
of cells. Gates were set based on antibody
binding to a representative age-matched
control (+/+) C57BL/6J mouse, and were
transferred to plots for the mutant animals
to compare relative location of subsets.
Rectangular gates represent those trans-
ferred from the +/+ control, while circular
gates identify new populations detected in
mutant mice. For the spleen, T-/B-depleted
cells were stained with antibodies specific
for CD11c, CD11b, CD8a and MHC-CII.
Live cells were gated by PI staining (data
not shown) and CD11cloCD8a,
CD11chiCD8a, CD11chiCD8a+ and
CD11cCD8a subsets gated for delinea-
tion of CD11b and MHC-II staining. This
allowed delineation of L-DC, pDC, CD8a+
cDC, CD8a cDC and monocytes. Analysis
of sanroque spleen (A), BM (B) and cervi-
cal LN (C) are shown.
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antigen or self-antigen. Indeed, their accessibility to blood-borne anti-
gen is noted here to be far superior to other DC subsets. Whilst
CD8a+ cDC and fresh splenic CD11c+ DC are known to be very good
activators of both CD8+ and CD4+ T cells, neither could take up suffi-
cient blood-borne antigen to induce proliferation of TCR-tg T cells in
the experiment described here involving in vivo priming. In contrast,
L-DC show a very strong T-cell activation response because of high
accessibility to antigen as well as strong cross-presenting capacity in
Fig. 5 Distribution of DC subsets in Rag/
mice. Twelve week-old Rag/ mice were
obtained from the Animal Services Division
(JCSMR). Spleen, bone marrow (BM), LN
and thymus were isolated and cells pre-
pared and stained as described in the leg-
end to Figure 1. A 12-week-old female
C57BL/6J mouse was used as a +/+ con-
trol. Cross-hairs were set based on binding
of isotype control antibodies and identifi-
able subsets of cells. Gates were set on the
control and transferred to the plots of cells
from two Rag/ mice, with rectangular
gates representing those transferred from
the +/+ control, and circular gates identify-
ing populations not present on the control
plots. Live cells were gated using PI stain-
ing (data not shown), and CD11cloCD8a,
CD11chiCD8a, CD11chiCD8a+ and
CD11cCD8a populations were gated for
delineation of CD11b and MHC-II expres-
sion on spleen (A), BM (B) and MLN (C) of
two Rag/ mice.
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the presence of LPS. The latter is a potent immunomodulatory mole-
cule, signalling through toll-like receptor (TLR) 4 on some APC [16].
It is also likely that L-DC respond to activation through up-regulation
of costimulatory molecules such as CD80, and production of cyto-
kines, which are so far not defined for this subset [17]. Further stud-
ies involving in vitro activation of carefully isolated subsets by cell
sorting will be needed to determine which cytokines are produced by
L-DC in comparison with other DC subsets. Studies are still in pro-
gress to define a mutant mouse strain or a protocol, which gives
numbers of cells suitable for more definitive studies of L-DC pheno-
type and function.
The exact location of L-DC in the spleen and how this location
changes in the event of inflammation are still under investigation. This
knowledge will almost certainly assist in determination of putative
functions for L-DC. The lack of MHC-II surface expression on L-DC in
the steady state is significant and could represent a tolerogenic role
for these cells in the absence of inflammation. Alternatively, low
MHC-II expression and high MHC-I expression [11] may indicate a
CD8+ T cell-specific role for L-DC, for example through cross-presen-
tation.
A cell phenotype of CD11cloCD11bhiCD8aMHC-II could also be
claimed to fit the phenotype of activated monocytes. Further analysis
of size and marker expression, however, rules against this possibility,
as it has been shown that L-DC express higher levels of MHC-I than
monocytes and are able to activate CD8 T cells in our assays ([11]
and Fig. 3B). Future studies will aim to determine markers and func-
tions that serve to distinguish these cell types.
Given the predicted myeloid origin of L-DC indicated by the high
level of CD11b expression, the existence of L-DC was examined in
mutant mouse strains known to have perturbations in myelopoiesis.
Mice lacking certain genes are a useful way to study cell development
for two reasons. First, mutants could be a better source of cells either
because of overproduction of the cell type in question or absence of
other cell types. Secondly, a mutant mouse strain may be of interest
if it specifically lacks the cell type of interest in terms of identifying
developmental origins. The phenotypes of L-DC in the mutant mouse
models sanroque and Rag/ reflect the state expected because of
the animal models. For example, L-DC in san/san animals show an
up-regulation of CD8a and MHC-II expression, possibly reflecting
activation of cells because of the constant inflammatory state induced
by autoimmunity. In Rag/ animals, by comparison, L-DC are not
evident in the spleen, possibly reflecting an inability to develop in the
absence of T- or B-cell-related factors. Crowley et al. [18] showed
that although lymphocytes are generally not essential to the organiza-
tion of the spleen and the presence of most DC subsets, lack of lym-
phocytes had a minor effect on marginal zone myeloid DC survival
and maturation, which, they suggested, could be due to a lack of B
cell-derived factors such as macrophage inflammatory factors a and
b. This was reflected in our experiments, where we observed cDC
populations in Rag-deficient mice, but report a lack of L-DC, which
are thought to be of a myeloid origin. As we hypothesize that L-DC
develop in the spleen [15], it is likely that similar factors are neces-
sary for L-DC development from spleen-resident HSC or progenitors.
In both cases, the mutant strain of interest did not serve to provide
higher numbers of L-DC required to perform a more complete analy-
sis of their function. These experiments have demonstrated that the
same L-DC are not present in the mutant strains investigated. The
distribution and phenotypes of the DC subsets and monocytes identi-
fied, however, are indicative of the known characteristics of each
mutant. For example, L-DC in the spleen of san/san animals could
have an inflammatory phenotype, whilst more undifferentiated mye-
loid cells are present in spleen of Rag/ animals.
Conclusion
From these experiments, it is evident that L-DC represent a small but
distinct subset of dendritic-like cells in the spleen. A similar cell type
is also present in BM, although future studies will need to determine
whether they represent the same subset. Although the function of L-
DC is still under investigation, it is thought that they reflect a unique
subset that will demonstrate unique function specific to their predom-
inant location in spleen and blood.
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